// App-Quantinova.ai

E098 : Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542)

Researchers

Presenter

  • Robert Landewe

Principal Investigators

  • Desiree van der Heijde

  • Maxime Dougados

  • Xenofon Baraliakos

  • Filip Van den Bosch

  • Karl Gaffney

  • Bengt Hoepken

  • Karen Thomas

  • Lianne S Gensler

Medical Centers

  • Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland Medical Center, Heerlen, NETHERLANDS

  • Department of Rheumatology, Leiden University Medical Centre, Leiden, UK

  • Rheumatology A department and INSERM U, Paris Descartes University, Cochin Hospital, Paris, France

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

  • Hematology, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

  • Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UNITED KINGDOM

  • Immunology, UCB Pharma, Monheim, GERMANY

  • UCSF Medical Center, University of California, San Francisco, CA

Locations

  • Netherlands

  • France

  • Germany

  • Belgium

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

  • Parallel Group

Phase

  • NA

Study Id's

  • NCT02505542

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved